Prescribe by brand
Admelog (Insulin Lispro biosimilar)
GREEN: 100units/ml - preferred cost-effective brand. (decision date - June 2023)
Humalog (Insulin Lispro)
GREY: 100units/ml - New patient should consider Admelog as the cost-effective choice. Existing patients on Humalog should continue on treatment until the next clinical review takes place to assess if suitable for switching. (decision date - June 2023)
GREY: 200units/ml* (decision date - October 2017)
Lyumjev (Insulin Lispro)
GREEN: 100units/ml
GREY: 200units/ml* (Decision date - October 2020)
Lispro Sanofi (Insulin Lispro biosimilar)
DO NOT PRESCRIBE (DNP): 100units/ml. (Decision based on lack of clarity between biosimilar and originator name and the risk of inadvertent switching) (Decision date - September 2018)
*See MHRA April 2015, High strength, fixed combination and biosimilar insulin products to minimise the risk of medication error.
